Crossmark

Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis

Published Online: 2023-03-17

Published Print: 2023-05

Authors

Dalal, Rahul S.

Goksel, Behiye

Hamilton, Matthew J.
License Information

Text and Data Mining valid from 2023-03-17

Version of Record valid from 2023-03-17
More Information

Article History

Accepted: 28 January 2023

First Online: 17 March 2023

Declarations

:

: Matthew Hamilton: Educational grants from Takeda, Abbvie, Pfizer; Rahul Dalal: Research grants from Janssen and Pfizer, consultant for Janssen and Centaur labs; Behiye Goksel: None.

Document is current